慢性炎症疾病患者小分子药物暴露高于健康志愿者:近期获批药物分析
综述量化过去15年FDA批准用于慢性炎症适应症的小分子药物在患者与健康志愿者间的(表观)清除率差异。基于群体药代动力学分析,25%(5/20)的药物在患者中AUC较健康志愿者高逾25%,这5个药物均主要经CYP3A4或CYP2C19代谢。提示从健康志愿者向患者剂量转化时需评估药物对慢性炎症下代谢活性变化的敏感性。
要点
- 25%(5/20)慢性炎症适应症小分子药物在患者中AUC较健康志愿者高逾25%。
- 上述5药均主要经CYP3A4或CYP2C19代谢,其中4药代谢清除贡献超50%。
- 健康志愿者向患者剂量转化时应评估慢性炎症对代谢活性的影响。
核心结论
- 部分慢性炎症适应症小分子药物在患者中的暴露高于健康志愿者,与CYP3A4或CYP2C19代谢相关。
研究设计与样本
- 综述基于FDA过去15年批准用于重要慢性炎症适应症的小分子药物的已发表群体药代动力学分析。
主要发现
- 25%(5/20)的小分子药物在患者中AUC较健康志愿者高逾25%。
- 5个药物均主要经CYP3A4或CYP2C19代谢,其中4个药物代谢对消除的贡献超过50%。
关键数值与推荐
- AUC升高阈值定义为患者较健康志愿者高逾25%。
- 代谢贡献超过50%见于5个药物中的4个。
临床怎么用
- 从健康志愿者向患者转化剂量预测时,应评估药物对慢性炎症下代谢活性变化的敏感性。
- 关注主要经CYP3A4或CYP2C19代谢且代谢清除贡献高的药物在慢性炎症患者中的暴露差异。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic inflammation has long been known to downregulate the activity of certain cytochrome P450 (CYP) enzymes—the main enzymes responsible for the phase I metabolism of many small molecule drugs—potentially leading to higher exposures in patients with chronic inflammatory diseases compared to healthy volunteers. Neglecting this potential difference in the pharmacokinetics can have several implications for dose translation from healthy volunteers to proof of concept studies in patients: sub-optimal design of dose-ranging studies and increased risk of adverse events due to overprediction of safety margins. Yet this disease–drug interaction has rarely been prospectively considered in drug development in the past. This review aims to quantify the extent of decreased (apparent) clearance in patients compared to healthy volunteers of small molecule drugs that were approved by the FDA in the past 15 years for important chronic inflammatory indications. Based on reported population pharmacokinetic analyses, 25% (5 of 20) of small molecule drugs approved for the selected indications showed a meaningfully higher area under the curve (AUC) by more than 25% in patients compared to healthy volunteers. As a common feature, all five drugs are primarily metabolized by CYP3A4 or CYP2C19 and for four of the five drugs, the contribution of metabolism to their elimination is more than 50%. These findings highlight the need to assess a drug's susceptibility to changes in the metabolic activity under chronic inflammation when translating dose predictions from healthy volunteers to patients.
引用
- Clinical Pharmacology & Therapeutics:Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。